每(mei)經(jing)AI快訊，1月8日(ri)，中國醫(yi)藥公(gong)(gong)告，公(gong)(gong)司(si)收(shou)到(dao)《關(guan)于重(zhong)(zhong)(zhong)(zhong)(zhong)慶化(hua)醫(yi)控(kong)股(gu)(gu)(gu)(集團)公(gong)(gong)司(si)提(ti)請召開重(zhong)(zhong)(zhong)(zhong)(zhong)慶醫(yi)藥健(jian)康產(chan)業有限公(gong)(gong)司(si)股(gu)(gu)(gu)東會(hui)臨時會(hui)議(yi)的(de)(de)函報告》，參股(gu)(gu)(gu)公(gong)(gong)司(si)重(zhong)(zhong)(zhong)(zhong)(zhong)慶醫(yi)健(jian)股(gu)(gu)(gu)東重(zhong)(zhong)(zhong)(zhong)(zhong)慶化(hua)醫(yi)集團擬(ni)將其所持重(zhong)(zhong)(zhong)(zhong)(zhong)慶醫(yi)健(jian)49%股(gu)(gu)(gu)權(quan)(quan)(quan)采(cai)取(qu)非公(gong)(gong)開協議(yi)方式轉(zhuan)讓給重(zhong)(zhong)(zhong)(zhong)(zhong)慶渝富，股(gu)(gu)(gu)權(quan)(quan)(quan)轉(zhuan)讓價格為45.07億元。公(gong)(gong)司(si)擬(ni)放(fang)棄該(gai)49%股(gu)(gu)(gu)權(quan)(quan)(quan)的(de)(de)優先(xian)購(gou)(gou)買(mai)(mai)權(quan)(quan)(quan)。本(ben)次(ci)放(fang)棄優先(xian)購(gou)(gou)買(mai)(mai)權(quan)(quan)(quan)事項(xiang)不(bu)構成(cheng)(cheng)關(guan)聯交易(yi)，亦不(bu)構成(cheng)(cheng)重(zhong)(zhong)(zhong)(zhong)(zhong)大資產(chan)重(zhong)(zhong)(zhong)(zhong)(zhong)組情(qing)(qing)形(xing)(xing)。本(ben)次(ci)放(fang)棄優先(xian)購(gou)(gou)買(mai)(mai)權(quan)(quan)(quan)事項(xiang)經(jing)公(gong)(gong)司(si)第九屆董事會(hui)第22次(ci)會(hui)議(yi)審議(yi)通過，尚需提(ti)交股(gu)(gu)(gu)東大會(hui)審議(yi)。本(ben)次(ci)放(fang)棄優先(xian)購(gou)(gou)買(mai)(mai)權(quan)(quan)(quan)未導致公(gong)(gong)司(si)合(he)并報表范(fan)圍發生變(bian)化(hua)，亦不(bu)會(hui)導致公(gong)(gong)司(si)對重(zhong)(zhong)(zhong)(zhong)(zhong)慶醫(yi)健(jian)的(de)(de)持股(gu)(gu)(gu)比例下降。不(bu)存(cun)在(zai)損害公(gong)(gong)司(si)及(ji)公(gong)(gong)司(si)股(gu)(gu)(gu)東利益的(de)(de)情(qing)(qing)形(xing)(xing)，不(bu)會(hui)對公(gong)(gong)司(si)財務及(ji)經(jing)營狀況產(chan)生重(zhong)(zhong)(zhong)(zhong)(zhong)大影響。